PKM and intrahepatic cholangiocarcinoma: FGFR2 inhibition in patient-derived intrahepatic cholangiocarcinoma (ICC) cell lines containing an overactive FGFR2 mutant decreases HK2, PKM2, and LDHA expression (Zhen et al., 2024).